http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-035203-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7ad58d3c0b071069a8ee0cb8c8ba2e8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-14 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C229-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C317-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C237-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C229-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C323-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C237-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D263-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D333-20 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C317-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C229-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D263-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C229-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C237-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C323-52 |
| filingDate | 2001-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2004-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-035203-A1 |
| titleOfInvention | DERIVATIVES OF PROPIONIC ACID, A PROCEDURE FOR ITS PREPARATION, MEDICATIONS, PROCEDURE FOR THE PREPARATION OF MEDICINES, AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF MEDICINES |
| abstract | Derivatives of propionic acid, comprising compounds of the general formula (1) in which: A represents a bond or a group -CH2- or -CH2-CH2-; X represents O, S or CH2; R1, R2 and R3 are the same or different and independently represent each other, hydrogen, C1-6 alkyl, C3-7 cycloalkyl, hydroxyl, C1-6 alkoxy, C6-10 aryloxy, halogen, trifluoromethyl, trifluoromethoxy, C1-6 alkylaminosulfonyl , nitro or cyano, or R1 and R2 are attached to two adjacent C atoms and together with these form a fused cyclohexane or benzene ring, the latter being optionally substituted with a C1-4 alkylsulfonylmethyl group, and R3 has the meaning indicated above; R4 represents hydrogen or C1-4 alkyl; R5 and R6 mean hydrogen or together with the C atom to which they are attached form a carbonyl group; R7 represents hydrogen, C1-6 alkyl, phenyl or benzyl, the indicated aromatic rings may be substituted in turn respectively 1 to 3 times by substituents the same or different from the group consisting of C1-6 alkyl, C1-6 alkoxy, hydroxyl or halogen; R8 represents hydrogen, C6-10 aryl or C1-4 alkyl, which in turn can be substituted with hydroxyl, trifluoromethoxy, C1-4 alkoxy or phenoxy, which in turn are optionally substituted 1 to 2 times with trifluoromethyl, or with C6-10 aryl or 5- or 6-membered heteroaryl with up to 3 heteroatoms of the N, O and S group, all indicated aryl and heteroaryl rings being substituted in turn respectively 1 to 3 times by substituents the same or different from the group consisting of halogen, hydroxyl, C1-6 alkyl, C1-6 alkoxy, trifluoromethyl, trifluoromethoxy, cyano, nitro and amino; R9 and R10 are the same or different and independently of each other represent hydrogen, C1-6 alkyl, C1-6 alkoxy, trifluoromethyl, trifluoromethoxy or halogen; R11 and R12 are the same or different and independently of each other represent hydrogen or C1-6 alkyl or together with the C atom to which they are attached form a C4-7 cycloalkyl ring; and R13 represents hydrogen or a hydrolysable group that can be degraded to the corresponding carboxylic acid; as well as its pharmaceutically acceptable salts, hydrates and solvates; a procedure for its preparation, medicaments, procedure for the preparation of medicaments and the use of said derivatives for the manufacture of medicaments for the prophylaxis and treatment of diseases, such as arteriosclerosis and as agonists of the peroxisome proliferator activated receptor, potent activators of PPAR-alpha for the treatment of, for example, coronary heart disease. Compounds comprising the formula (2) in which A, X, R7, R8, R9, R10, R11 and R12 have the meaning indicated above; and T represents benzyl, C1-6 alkyl a support polymer suitable for solid phase synthesis. |
| priorityDate | 2000-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 48.